Institutional investors may overlook Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) recent US$57m market cap drop as long-term gains remain positive

Simply Wall St.09-04

Key Insights Institutions' substantial holdings in Y-mAbs Therapeutics implies that they have significant influence over the company's share price The top 8 shareholders own 53% of the company ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2465285585?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2024-09-04 20:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2465285585","market":"us","top_or_hot":-1,"title":"Institutional investors may overlook Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) recent US$57m market cap drop as long-term gains remain positive","media":"Simply Wall St.","content":"<div>\n<p>Key Insights  Institutions' substantial holdings in Y-mAbs Therapeutics implies that they have significant influence over the company's share price   The top 8 shareholders own 53% of the company    ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ymab/y-mabs-therapeutics/news/institutional-investors-may-overlook-y-mabs-therapeutics-inc\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Institutional investors may overlook Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) recent US$57m market cap drop as long-term gains remain positive</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInstitutional investors may overlook Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) recent US$57m market cap drop as long-term gains remain positive\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-04 20:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ymab/y-mabs-therapeutics/news/institutional-investors-may-overlook-y-mabs-therapeutics-inc><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key Insights  Institutions' substantial holdings in Y-mAbs Therapeutics implies that they have significant influence over the company's share price   The top 8 shareholders own 53% of the company    ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ymab/y-mabs-therapeutics/news/institutional-investors-may-overlook-y-mabs-therapeutics-inc\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2210150020.SGD","symbol_name":"Natixis Thematics Subscription Economy R/A SGD","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ymab/y-mabs-therapeutics/news/institutional-investors-may-overlook-y-mabs-therapeutics-inc","article_id":"2465285585","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2465285585","pubTimestamp":1725451371,"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Key Insights Institutions' substantial holdings in Y-mAbs Therapeutics implies that they have significant influence...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","QLD":"纳指两倍做多ETF","BK4585":"ETF&股票定投概念","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","YMAB":"Y-mAbs Therapeutics, Inc.","SQQQ":"纳指三倍做空ETF","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","NDAQ":"纳斯达克OMX交易所","BK4139":"生物科技","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","QID":"纳指两倍做空ETF","TQQQ":"纳指三倍做多ETF",".IXIC":"NASDAQ Composite","PSQ":"纳指反向ETF","BK4112":"金融交易所和数据","BK4588":"碎股"},"translate_title":"机构投资者可能会忽视Y-mAbs Therapeutics,Inc.（纳斯达克股票代码：YMAB）最近5700万美元的市值下跌，因为长期收益仍然为正","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"YMAB":1,"NDAQ":1,".IXIC":1,"TQQQ":0.6,"SQQQ":0.6,"QLD":0.6,"QID":0.6,"PSQ":0.6,"NQmain":0.6,"MNQmain":0.6},"content_text":"Key Insights  Institutions' substantial holdings in Y-mAbs Therapeutics implies that they have significant influence over the company's share price   The top 8 shareholders own 53% of the company    Insiders have been selling lately    If you want to know who really controls Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB), then you'll have to look at the makeup of its share registry.  We can see that institutions own the lion's share in the company with 46% ownership.  Put another way, the group faces the maximum upside potential (or downside risk).  Institutional investors endured the highest losses after the company's market cap fell by US$57m last week.  However, the 182% one-year returns may have helped alleviate their overall losses.  They should, however, be mindful of further losses in the future.     In the chart below, we zoom in on the different ownership groups of Y-mAbs Therapeutics.  View our latest analysis for Y-mAbs Therapeutics NasdaqGS:YMAB Ownership Breakdown September 4th 2024 What Does The Institutional Ownership Tell Us About Y-mAbs Therapeutics? Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.   We can see that Y-mAbs Therapeutics does have institutional investors; and they hold a good portion of the company's stock.  This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does.  If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Y-mAbs Therapeutics' earnings history below. Of course, the future is what really matters. NasdaqGS:YMAB Earnings and Revenue Growth September 4th 2024  It would appear that 8.7% of Y-mAbs Therapeutics shares are controlled by hedge funds.  That catches my attention because hedge funds sometimes try to influence management, or bring about changes that will create near term value for shareholders.      Wg Biotech Aps is currently the largest shareholder, with 10% of shares outstanding.       Meanwhile, the second and third largest shareholders, hold 8.7% and 7.4%, of the shares outstanding, respectively.     We also observed that the top 8 shareholders account for more than half of the share register, with a few smaller shareholders to balance the interests of the larger ones to a certain extent.     Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments.   Quite a few analysts cover the stock, so you could look into forecast growth quite easily.  Insider Ownership Of Y-mAbs Therapeutics The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least.  Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.  I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.   We can report that insiders do own shares in Y-mAbs Therapeutics, Inc..   As individuals, the insiders collectively own US$18m worth of the US$638m company.   This shows at least some alignment. You can  click here to see if those insiders have been buying or selling.   General Public Ownership With a 18% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Y-mAbs Therapeutics.  While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.   Private Equity Ownership With a stake of 14%, private equity firms could influence the Y-mAbs Therapeutics board.   Some investors might be encouraged by this, since private equity are sometimes able to encourage strategies that help the market see the value in the company. Alternatively, those holders might be exiting the investment after taking it public.   Private Company Ownership Our data indicates that Private Companies hold 10%, of the company's shares.   It might be worth looking deeper into this. If related parties, such as insiders, have an interest in one of these private companies, that should be disclosed in the annual report. Private companies may also have a strategic interest in the company.   Next Steps: It's always worth thinking about the different groups who own shares in a company. But to understand Y-mAbs Therapeutics better, we need to consider many other factors.    Case in point: We've spotted   4 warning signs for Y-mAbs Therapeutics  you should be aware of, and 1 of them makes us a bit uncomfortable.      But ultimately  it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future.  NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2465285585"}